Neurogene Inc. (NGNE) — Stock Price, Chart & Analysis
Neurogene Inc. (NGNE) is a Healthcare stock currently trading at $33.6, up 3.16% on the day. It carries a market capitalization of $672.38M. Over the past 52 weeks, NGNE has traded between $15.93 and $43.66. Neurogene Inc. does not currently pay a regular dividend. View the live NGNE chart, technical opinion, analyst ratings, fundamentals and latest news below.
Neurogene Inc. (NGNE) key data
| Price | $33.6 |
| Change (today) | +3.16% |
| Previous close | $32.57 |
| Market cap | $672.38M |
| EPS (TTM) | $-5.19 |
| 52-week high | $43.66 |
| 52-week low | $15.93 |
| Beta | 1.96 |
| Avg. volume | 260.3K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Neurogene Inc. (NGNE)
How much does one share of Neurogene Inc. cost?
As of the latest update, one share of Neurogene Inc. (NGNE) trades at $33.6 (+3.16% today).
What is Neurogene Inc.'s market cap?
Neurogene Inc. has a market capitalization of approximately $672.38M.
What is Neurogene Inc.'s earnings per share (EPS)?
Neurogene Inc.'s trailing twelve-month EPS is $-5.19.
Does Neurogene Inc. pay a dividend?
Neurogene Inc. does not currently pay a regular dividend.
What is Neurogene Inc.'s 52-week trading range?
Over the past year, NGNE has traded between $15.93 and $43.66.
What is the analyst price target for Neurogene Inc.?
The mean analyst price target for Neurogene Inc. is $80.43. This is informational only and not investment advice.
Latest Neurogene Inc. (NGNE) news
- Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceNews · Sep 8, 2026
- Neurogene Inc. Announces Pricing of $125 Million Public OfferingNews · Jul 1, 2026
- Neurogene Inc. Announces Proposed Public OfferingNews · Jun 30, 2026
- We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business GrowthNews · May 5, 2026
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)News · Jun 2, 2026
- Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett SyndromeNews · Jun 29, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NGNE dashboard…